convalescent plasma-Hospital de Clinicas de Porto Alegre-COVID-19

Convalescent plasma-Hospital de Clinicas de Porto Alegre-COVID-19 refers to the specific convalescent plasma therapy investigated in the PLACOVID trial (NCT04547660) by the Hospital de Clínicas de Porto Alegre. This biologic therapy involves the transfusion of plasma from donors who have recovered from COVID-19, containing high titers of neutralizing antibodies against SARS-CoV-2. The mechanism of action is passive immunotherapy, where these antibodies bind to the virus—specifically the spike protein—to neutralize it and prevent infection of host cells. The Phase 3 trial evaluated its efficacy in severe or critically ill hospitalized patients, finding that two infusions of the plasma did not significantly improve clinical outcomes at day 28 compared to standard care.

Other names

Convalescent PlasmaPLACOVID trial plasma